![Qinglei Zuo](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Qinglei Zuo
Corporate Officer/Principal chez
OCUMENSION THERAPEUTICS
Profil
Qinglei Zuo is the Chief Commercial Officer at Ocumension Therapeutics since 2021.
Prior to this, he worked as the Head of Sales and Director of Business Development at Santen Pharmaceutical (China) Co. Ltd. from 2015 to 2018, Manager of Product and District Sales at Eisai China, Inc. from 2010 to 2015, and Project Manager of the Research and Development Department at Shanghai Hengrui Pharmaceutical Co., Ltd. from 2009 to 2010.
He graduated from Shanghai Institute of Pharmaceutical Industry in 2009 with a graduate degree and from Yantai University in 2006 with an undergraduate degree.
Postes actifs de Qinglei Zuo
| Sociétés | Poste | Début |
|---|---|---|
| OCUMENSION THERAPEUTICS | Corporate Officer/Principal | 01/01/2021 |
Anciens postes connus de Qinglei Zuo
| Sociétés | Poste | Fin |
|---|---|---|
Santen Pharmaceutical (China) Co. Ltd.
 Santen Pharmaceutical (China) Co. Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and wholesales ophthalmic pharmaceuticals | Sales & Marketing | 01/08/2018 |
Eisai China, Inc.
 Eisai China, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Corporate Officer/Principal | 01/03/2015 |
Shanghai Hengrui Pharmaceutical Co., Ltd.
 Shanghai Hengrui Pharmaceutical Co., Ltd. Shanghai Hengrui Pharmaceutical Co., Ltd. specializes in the research, development, and promotion of innovative and high-quality drugs, with a focus on early-stage drug discovery. Shanghai Hengrui’s therapeutic areas include oncology, metabolism, cardiovascular diseases, autoimmune disorders, pain management, immune and respiratory diseases, and neuroscience. The company is based in Shanghai, China. The Chinese company operates advanced research laboratories and GMP-compliant production facilities, serving as the core innovation base for Hengrui Medicine. It is a major supplier of anti-tumor drugs, surgical medications, and imaging interventional products, and has developed proprietary technology platforms such as single B cell sequencing, bispecific and multispecific antibodies, antibody-drug conjugates, PROTAC technology, T cell engagers, and computer-aided drug design. The company has brought multiple innovative drugs to market, including early-developed class 1 innovative drugs for cancer, diabetes, and hematological diseases, and maintains a broad pipeline of drug candidates in preclinical and clinical phases, including targeted cancer therapies. | Corporate Officer/Principal | 01/09/2010 |
Formation de Qinglei Zuo
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
40
Relations au 1er degré
6
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Shanghai Institute of Pharmaceutical Industry
 Shanghai Institute of Pharmaceutical Industry Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Yantai University
 Yantai University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Santen Pharmaceutical (China) Co. Ltd.
Santen Pharmaceutical (China) Co. Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and wholesales ophthalmic pharmaceuticals | Health Technology |
Eisai China, Inc.
Eisai China, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Shanghai Hengrui Pharmaceutical Co., Ltd.
Shanghai Hengrui Pharmaceutical Co., Ltd. Shanghai Hengrui Pharmaceutical Co., Ltd. specializes in the research, development, and promotion of innovative and high-quality drugs, with a focus on early-stage drug discovery. Shanghai Hengrui’s therapeutic areas include oncology, metabolism, cardiovascular diseases, autoimmune disorders, pain management, immune and respiratory diseases, and neuroscience. The company is based in Shanghai, China. The Chinese company operates advanced research laboratories and GMP-compliant production facilities, serving as the core innovation base for Hengrui Medicine. It is a major supplier of anti-tumor drugs, surgical medications, and imaging interventional products, and has developed proprietary technology platforms such as single B cell sequencing, bispecific and multispecific antibodies, antibody-drug conjugates, PROTAC technology, T cell engagers, and computer-aided drug design. The company has brought multiple innovative drugs to market, including early-developed class 1 innovative drugs for cancer, diabetes, and hematological diseases, and maintains a broad pipeline of drug candidates in preclinical and clinical phases, including targeted cancer therapies. | |
Ocumension Therapeutics
 Ocumension Therapeutics Miscellaneous Commercial ServicesCommercial Services Operates as an ophthalmic pharmaceutical platform company that develops drugs | Commercial Services |
